Kawasaki Disease — What Five Days of Fever Means

4 min read日本語版あり
Audience
Parents of children 0–5 years
Target length
~1,400 words
Status
Draft v1 (translated from Japanese v1)
Original
../235_kawasaki_disease.md

Lead

"The fever has been going on for five days" — this statement shifts the thinking of a pediatrician in a particular way. Most fevers resolve in three to four days. When five days have passed, Kawasaki disease moves near the top of the differential.

Kawasaki disease is a vasculitis that affects more than 15,000 infants and young children in Japan each year [1,2]. Without appropriate treatment, one in five patients may develop coronary artery aneurysms — a cardiac complication with potentially lasting consequences [1,2]. With timely treatment, that risk drops substantially. The most important thing a parent can do is recognize the characteristic combination of symptoms.

What Is Kawasaki Disease?

Kawasaki disease is a systemic syndrome first reported in 1967 by pediatrician Tomisaku Kawasaki [1]. Its cause remains unknown, but the prevailing hypothesis is that some infectious trigger sets off an exaggerated immune response, leading to inflammation of medium-sized blood vessels throughout the body.

Cases are concentrated in children under 5 years old, with the highest incidence in infants aged 6 months to 2 years [2]. Boys are affected approximately 1.3 times more often than girls. Japan has the highest reported incidence in the world, and the epidemiological distinctiveness has prompted research into possible genetic predispositions [2].

The Six Principal Features

Diagnosis relies on a combination of findings. The classical case is defined by fever persisting for five or more days plus at least four of the following five criteria:

  1. Bilateral conjunctival injection — redness of both eyes, typically without discharge
  2. Oral and labial changes — redness and cracking of the lips, a strawberry-appearing tongue, or pharyngeal redness
  3. Rash — a polymorphous rash distributed over the trunk and extremities
  4. Changes in the extremities — in the acute phase: swelling and redness of the hands and feet; in the recovery phase: peeling skin beginning at the fingertips
  5. Non-purulent cervical lymphadenopathy — cervical lymph nodes enlarged to 1.5 cm or more

These features rarely appear all at once. Fever typically precedes the others, which may develop over the following days. An "incomplete" form — meeting fewer than four criteria — accounts for 10–20% of all cases and is more likely to be missed [1]. Persistent unexplained fever beyond five days, even without the full complement of features, should prompt consideration of Kawasaki disease including the incomplete form.

Treatment and the Risk of Coronary Artery Aneurysms

Without treatment, coronary artery dilation or aneurysm formation occurs in 20–25% of patients. This is the central danger of the disease. Coronary aneurysms involve localized ballooning of the arterial wall and can lead to thrombosis or myocardial infarction [1].

The standard treatment is a single infusion of intravenous immunoglobulin (IVIG) at 2 g/kg, combined with aspirin. This regimen reduces the incidence of coronary artery abnormalities to approximately 5% [1,4]. Treatment administered within the first seven days of fever — before the inflammatory process is fully established — is associated with better outcomes, which is why diagnostic delay increases risk.

Approximately 10–20% of patients do not respond to the initial IVIG infusion and require additional treatment — the so-called IVIG-unresponsive group [1,5]. Options in this situation include infliximab, cyclosporine, or a second course of IVIG.

Children who develop coronary aneurysms require long-term management with aspirin and, in some cases, anticoagulant therapy. Severe cases may need continued cardiology follow-up into adulthood.

What Parents Can Do — Observation and Records

There is no single diagnostic test for Kawasaki disease. Physicians evaluate the combination of findings and the course of illness together. This makes a parent's observations a genuinely important source of diagnostic information.

Waiting through "it's probably just a long cold" is understandable, but when fever continues past day five, actively checking whether other features have joined — and seeking evaluation — may accelerate diagnosis and treatment. Recording symptoms and temperature trends in a parenting log app means arriving at the pediatrician's office with an accurate account of the timeline. Kawasaki disease is an illness where the sequence of events matters to the diagnosis.

Summary

Kawasaki disease is a vasculitis of unknown cause, but it has well-defined diagnostic criteria, and when treatment is started early, the risk of cardiac complications is substantially reduced. When five or more days of fever coincide with changes in the eyes, lips, skin, hands and feet, or lymph nodes, Kawasaki disease warrants consideration and a pediatric visit. Japan has the highest incidence of this disease in the world — a fact that is worth knowing.

References

  1. McCrindle BW, Rowley AH, Newburger JW, et al.; American Heart Association. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement from the American Heart Association. Circulation. 2017;135(17):e927–e999. doi:10.1161/CIR.0000000000000484. PMID: 28356445.
  2. Nakamura Y, Yashiro M, Uehara R, et al. Epidemiologic features of Kawasaki disease in Japan: results from the nationwide survey in 2009–2010. J Epidemiol. 2012;22(3):216–221. doi:10.2188/jea.JE20110126. PMID: 22447211.
  3. Newburger JW, Takahashi M, Gerber MA, et al.; American Heart Association. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals. Pediatrics. 2004;114(6):1708–1733. doi:10.1542/peds.2004-2182. PMID: 15574639.
  4. Kobayashi T, Saji T, Otani T, et al.; RAISE study group. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study). Lancet. 2012;379(9826):1613–1620. doi:10.1016/S0140-6736(11)61930-2. PMID: 22405251.
  5. Tremoulet AH, Jain S, Jaggi P, et al. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet. 2014;383(9930):1731–1738. doi:10.1016/S0140-6736(13)62298-9. PMID: 24572997.

Related